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ABSTRACT  
The disruption of the Circadian Timing System (CTS), which rhythmically controls cellular 
metabolism and proliferation, accelerated experimental cancer progression. A measure of 
CTS function in cancer patients could thus provide novel prediction information for 
outcomes, and help identify novel specific therapies. The rest-activity circadian rhythm is a 
reliable and non invasive CTS biomarker, which was monitored using a wrist watch 
accelerometer for 2 days in 436 patients with metastatic colorectal cancer. The relative 
percentage of activity in-bed versus out-of-bed (I<O) constituted the tested CTS measure, 
whose prognostic value for overall survival (OS) and progression-free survival (PFS) was 
determined in a pooled analysis of three patient cohorts with different treatment exposures. 
Median OS was 21.6 months [17.8-25.5] for patients with I<O above the median value of 
97.5% as compared to 11.9 months [10.4-13.3] for those with a lower I<O (Logrank 
p<0.001). Multivariate analyses retained continuous I<O as a joint predictor of both OS and 
PFS, with respective Hazard Ratios (HR) of 0.954 (p<0.001) and 0.970 (p<0.001) for each 
1% increase in I<O. HRs had similar values in all the patient subgroups tested. The circadian 
physiology biomarker I<O constitutes a robust and independent quantitative predictor of 
cancer patient outcomes, that can be easily and cost-effectively measured during daily living. 
Interventional studies involving 24-h schedules of clock-targeted drugs, light intensity, 
exercise and/or meals are needed for testing the relevance of circadia  synchronization for the 
survival of patients with disrupted rhythms. 
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INTRODUCTION 
Circadian rhythms are potential biomarkers related to health and diseases. These rhythms are 
generated at single cell level by a molecular clock involving at least 15 specific genes (Dibner 
et al., 2010). The cellular clocks are coordinated by the suprachiasmatic nuclei (SCN) in the 
hypothalamus, a pacemaker that further adjusts the circadian rhythms to the environmental 
day-night cycles (Dibner et al., 2010). Experimental data further show that the network of 
molecular clocks that constitute the Circadian Timing System (CTS) is a control point for 
tumor progression. Thus cancer progression was accelerated two- to three-fold in tumor-
bearing mice whose rest-activity rhythm was suppressed as a result of SCN ablation or 
chronic ‘jet lag’ (Fu et al., 2002; Filipski et al., 2002). Conversely CTS amplification through 
programmed daily meal timing halved experimental cancer growth in mice (Wu et al., 2004, 
Li et al., 2010). Here we investigated the clinical relevance of such preclinical findings in a 
large sample of cancer patients, using non invasive technology.  
The rest-activity rhythm constitutes a clinically relevant circadian biomarker, since it is 
amenable to non-invasive monitoring with a wrist watch accelerometer (Mormont et al., 
2000). The quest for circadian biomarkers of human health is further supported by the 
demonstration of an increased risk of cancer in shift workers exposed to occupational 
schedules that disrupt  circadian rhythms (IARC-Working-Group, 2010). The human CTS is 
synchronized by environmental light-dark alternation, as well as by socio-professional routine 
and meal timing, whose iterative and sustained alterations disrupt the CTS (Levi et al., 2010). 
Such disruption has been documented using several parameters derived from wrist actimetry 
monitoring (Mormont et al., 2000; Ancoli-Israel et al., 2003; Berger et al.,2008). Several such 
devices have been approved for human use, yet their specific technical design and the time 
series analyses methods that are used can influence the parameter values that are obtained. 
Using the Minimotion logger actimeter®, we first revealed the clinical relevance of the 
Page 5 of 28
URL: http://mc.manuscriptcentral.com/lcbi E-mail: Francesco Portaluppi prf@unife.it
Chronobiology International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Chronobiology International by F LEVI 02/05/2014 
5 
 
dichotomy index I<O, a measure of the percentage of in‐bed activity counts that are less than 
the median of out‐of‐bed counts (Mormont et al., 2000; Minors et al., 1996). Thus, in two 
previous cohort studies, I<O provided consistent prognostic information on the survival of 
patients with metastatic colorectal cancer (Mormont et al., 2000; Innominato et al., 2009a). 
Cohort I was a single institution study that included 192 consecutive patients mostly receiving 
chronomodulated 5-Fluorouracil-Leucovorin-Oxaliplatin chemotherapy after failure of a first 
treatment protocol (Mormont et al., 2000). Cohort II consisted of 130 chemo-naïve patients 
receiving chronomodulated or conventional delivery of the same 3-drug protocol within a 
randomized international Phase III trial (Innominato et al., 2009a). Such easily measurable 
circadian biomarkers that predict patient survival outcome have the potential for improving 
cancer care through the assessment of prognosis, the prediction of response to specific 
treatments, as well as the identification of novel circadian therapeutics (Buyse et al., 2010).  
Here, we first aimed at confirming the prognostic value of I<O as a circadian biomarker 
within a third cohort of 142 patients with metastatic colorectal cancer. These patients then 
received salvage multidrug chronotherapy as part of their routine oncology management after 
failure of chemotherapy for a majority of them. We then determined the prognostic value of 
I<O in a pooled analysis involving the 436 patients with metastatic colorectal cancer, accrued 
in the three aforementioned cohorts. The primary aim of such pooled analysis was to examine 
rest-activity rhythm as a circadian biomarker for the prediction of survival and progression-
free outcomes in patients with metastatic colorectal cancer, with adequate statistical power. A 
secondary aim was to explore the relations between the rest-activity circadian rhythm and 
outcomes in the main patient subgroups. This analysis was made possible by the large sample 
size of the pooled dataset. Such results were required before a broad routine implementation 
of this biomarker in the framework of personalized patient-centered cancer chronotherapy. 
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MATERIALS AND METHODS 
Patient cohorts and treatment regimens 
The pooled analysis involved 436 patients with metastatic colorectal cancer who had been 
enrolled in any of the three cohorts that prospectively investigated the relations between rest-
activity rhythm and patient outcomes from April 1994 to November 2006. The patients in 
these cohorts were subsets of clinical studies (Cohorts I and II) or had actimetry assessment as 
part of their routine chronotherapy management (Figure 1). Entry criteria in each of the three 
cohort studies included histological proof of colorectal cancer, measurable metastatic disease, 
WHO Performance Status less than 3, and signed written informed consent.  Eligible patients 
had a physical examination, Computed Tomography (CT) scan of the thorax, abdomen and 
pelvis, a complete blood count, and serum chemistry including CEA and CA19-9. All the 
patients had rest-activity recorded with a wrist watch “Mini-motion Logger” for a minimum 
of 48 h up to 7 days. The patients subsequently received at least one course of conventional or 
circadian-based chemotherapy (chronotherapy) involving oxaliplatin (O), irinotecan (I) or 
both, eventually combined with 5-fluorouracil (F) and Leucovorin (L) (Levi et al., 1997; 
Gholam et al., 2006). ChronoFL consisted in four consecutive daily chronomodulated 
infusions of 5-fluorouracil (cumulative dose per course, 2800-3200 mg/m²) and leucovorin 
(1200 mg/m²) from 22:15 to 9:45, with peak delivery rate at 4:00 at night every 2 weeks 
(Giacchetti et al., 2000). ChronoFLO involved the addition of four daily chronomodulated 
oxaliplatin infusions from 10:15 to 21:45 with peak delivery rate at 16:00 (cumulative dose, 
85-100 mg/m²) (Giacchetti et al., 2006). For chronoIFL, irinotecan (180 mg/m²) was infused 
from 02:00 to 08:00 with peak delivery at 05:00 on day 1, then followed by chronoFL (garufi 
et al.,2006). The chronoIFLO schedule combined day1 chronomodulated irinotecan 
(180mg/m²) with day2-5 chronoFLO (5-fluorouracil, 2800 mg/m², leucovorin, 1200 mg/m², 
oxaliplatin, 85 mg/m²) every 3 weeks (Gholam et al., 2006).  
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The characteristics of the patients in Cohorts I and II were previously reported (Mormont et 
al., 2000; Innominato et al., 2009a). The majority of the 142 patients in Cohort III (69%) had 
failed on prior chemotherapy for metastatic disease, while this was the case for none of the 
patients in Cohort II. Fifty-five percent and 33% of the patients in Cohort III had received 
prior oxaliplatin and irinotecan respectively, before rest-activity rhythm assessment. In 
contrast, these agents had been respectively administered to 1.8% and 5.4% of the patients in 
Cohort I (Mormont et al., 2000). The main chemotherapy protocols given after rest-activity 
assessment differed among the three cohorts. Patients in Cohort I received FL or FLO 
chronotherapy as first or second line chemotherapy (Giacchetti et al., 2000; Levi et al., 2007; 
Curé et al., 2002). Patients in Cohort II received first line chronoFLO or FOLFOX for 
metastatic disease (Innominato et al., 2009a; Giacchetti et al., 2006). Irinotecan-based 
chemotherapy was administered to 39.4% of the patients in Cohort III, and in none of the 
patients in either Cohort I or II. 
 
Efficacy endpoints 
Patients were followed for up to 10 years after actimetry recording. Response was assessed 
every third or fourth treatment course and defined according to WHO criteria (Jaffe, 2006). 
Independent radiology assessment was conducted for patients considered responders by the 
investigator. Patients were taken off the post actimetry treatment protocol as a result of 
progressive disease, lack of full recovery from severe toxicity, or complete surgical resection 
of metastases. Overall survival (OS) was defined as the time from first day of actimetry 
recording (day 0) to death or last time known alive. Patients who discontinued therapy for 
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reasons other than death or progression were censored at the drop out date. Progression-free 
survival (PFS) was also computed from day 0 to progression or death.  
 
 
Rest-activity rhythm monitoring 
To assess individual circadian rest-activity rhythm, a Mini-Motionlogger actigraph 
(Ambulatory Monitoring Inc., USA) was used. The actigraph looks similar to a watch and is 
worn on the non-dominant wrist. It contains a piezoelectric linear accelerometer to detect 
wrist movements and a memory chip for data storage. The time interval for the recording and 
count of activity level was 1 min. The actigraph was worn for at least 48 h continuously 
before the beginning of the first course of a new chemotherapy protocol.  
Actimetry time series analyses 
All actimetry time series were analyzed using a specific program (Action 4 version 1.10; 
Ambulatory Monitoring Inc., USA). The dichotomy index (I<O) was computed as the percent of 
time of activity in-bed, that is below the median level of activity out-of-bed (Mormont et al., 
2000; Minors et al., 1996). Thus, the primary measure, I<O, essentially assessed the reduction in 
physical activity while in-bed (I) compared to that when out-of-bed (O). A normal dichotomy 
index is one approaching 100%, indicating restful sleep and regular daily activity. The I<O 
measure is based upon 24 h of actimetry readings. Visual inspection of each day’s data indicated 
the approximate times of retiring and rising, based on sustained falls and rises in the activity 
counts, respectively. Activity counts during one hour before and one hour after each of these two 
times were ignored. This meant that a total of 20 h data per 24 h was considered, with a 
reasonable certainty that the data spans that were analysed indeed consisted of a section 
associated with attempted sleep (I, in bed) and another section associated with being awake (O, 
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out of bed). Daytime naps were included in the “awake” section. The median value of each of the 
two sections was then calculated, so that no assumption on data normalcy of distribution was 
required. I<O would be expected to approach 100% as a subject’s dichotomy (between in-bed 
inactivity and out-of bed activity) increased. Values of I<O in healthy controls are rarely <98% ( 
Minors et al., 1996). Lower values of I<O can be due to lower values of O and/or higher values 
of I. In practice, O (the median of all waking activity) rarely decreases sufficiently for it to exert 
a large influence on the index; it is usually a rise in activity counts during the time of attempted 
sleep that is the dominant factor in causing the I<O index to drop (Innominato et al., 2009a). 
Records examples and corresponding I<O values are shown in Figure 2. Neither the visual 
pattern of rest-activity nor the computed parameters were known by the clinician who prescribed 
the treatment protocol or took charge in patient management.  
Statistical methods 
Median and range were computed for I<O. The relations between patient characteristics and 
I<O upon study entry were tested using Kruskall-Wallis non-parametric tests for categorical 
variables and Pearson correlation for continuous variables. Median and interquartile range 
(IQR) were computed according to performance status, sex, number of metastastic sites and 
number of chemotherapy lines before actimetry measurements.  
For illustrating the prognostic role of I<O on OS and PFS, patients were split in two groups 
according to I<O value either above or below I<O median value, and the corresponding 
Kaplan-Meier survival curves were plotted. Logrank tests were performed for testing equality 
of survival functions. Multivariate analyses were performed using Cox proportional hazard 
models to investigate the effect of I<O on OS and PFS, in each patient cohort and in the 
whole study population. Variables with p<0.10 according to univariate analysis were selected 
(† in Table 1), and retained in the multivariate model using p<0.05 for the Wald test , using 
the forward stepwise selection procedure. In the pooled analysis, OS and PFS were analyzed 
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following stratification according to cohort, in order to account for differences in patient 
demographics, advancement of metastatic disease and treatment protocols after actimetry. 
These stratified Cox models allowed the underlying hazard function to vary across the 3 
cohorts. For each model, I<O was used as a continuous variable, and the proportional hazards 
assumption was evaluated by plotting the martingale residuals. Forest plots were drawn to 
illustrate the effect of I<O within different patient subgroups and to visualize the adjusted 
hazard ratios estimated in the multivariate Cox models and representing the effect of I<O on 
OS and PFS in each patient cohort and in the whole study population. All analyses were 
performed using R 2.15.2 and PASW Statistics 20 software (SPSS, Chicago, IL, USA).  
 
RESULTS 
The circadian patterns in rest-activity differed largely among individual patients with similar 
characteristics. Such inter-patient differences appeared to be adequately recapitulated in the 
computation of I<O (Figure 2). In the pooled patient population, I<O varied according to 
performance status, ranging from a median value of 98.2 [IQR: 95.4 to 99.3] for PS=0, to 96.5 
[93.1 to 99.0] for PS=1, and 91.5 [79.1 to 97.0]) for PS ≥2, with statistically significant 
differences in distribution (p from Kruskall-Wallis test <0.001). Median I<O was 97.1 [93.5 
to 99.0] in males, and 98.0 [94.1 to 99.4] in females (p = 0.04). The I<O distribution also 
varied according to number of metastatic sites, the medians ranging from 99.4 [98.2 to 99.9] 
in the patients without any detected metastasis, to 97.9 [94.1 to 99.2] in those with one 
metastatic site, and 97.1 [92.7 to 99.0] in the patients with ≥2 metastatic sites (p = 0.03). 
Median I<O values were similar in chemotherapy-naïve patients (97.5 [93.5 to 99.2]), as well 
as in patients previously treated with one (97.7 [94.5 to 99.1]) or ≥2 chemotherapy protocols 
(97.2 [92.9 to 99.2]) (Kruskall-Wallis, p = 0.84). 
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Cohort III  
The study enrolled 142 patients, who signed an informed consent form. Patients had poor 
prognosis disease as indicated by the administration of one to three conventional 
chemotherapy protocols to 69% of the patients, prior surgery for metastases among 41.5% of 
the patients, and prior administration of oxaliplatin and/or irinotecan for 55% and 33.1% of 
the patients respectively (Table 1). I<O ranged from 63.2 to 100%, with a median value of 
98.3%. The patients subsequently received chronoFLO (47.9%), irinotecan-based 
combination chronotherapy (39.4%), or another schedule (12.7%). 
Patients with I<O above its median value had a better overall survival than those with a lower 
I<O (p=0.006), with respective median survival of 23.3 months [95% Confidence.Interval, 
13.6 to 33.0] versus 14.1 months [95% C.I., 9.1 to 19.2] (curves not shown). Similarly, 
median PFS was 7.4 months [95% C.I., 5.4 to 9.5] in the patients with I<O above 98.3% as 
compared to 5.1 months [95% C.I., 2.8 to 7.3] in those with lower I<O value (curves not 
shown). However, the PFS curves did not differ significantly according to median of I<O 
(p=0.068). Multivariate analysis revealed continuous I<O as an independent prognostic factor 
for overall survival, along with performance status, number of metastatic sites, number of 
prior chemotherapy protocols, and subsequent surgery for metastases (results not shown). The 
adjusted hazard ratio corresponding to a one percent increase of I<O was 0.953 [95% C.I., 
0.924 to 0.984] (p=0.003). 
 
POOLED PATIENT POPULATION 
Patient characteristics 
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The updated patient data from the patients in Cohorts I and II were pooled with the patient 
data from Cohort III (Table 1). Overall, a total of 436 patients with metastatic colorectal 
cancer had adequate longitudinal assessment of their rest-activity rhythm for time series 
analysis (Figure 1). The pooled sample consisted of 37.4% women and 62.6% men from four 
countries. Fifty-one percent of the patients had two or more metastatic sites. Prior 
chemotherapy for metastatic disease had been administered to 45.4% of the patients. 
Following rest-activity rhythm assessment, chemotherapy was administered as a conventional 
modality for 71 patients (16.4%) (Giacchetti et al., 2000, Giacchetti et al., 2006) or as 
chronotherapy for 360 patients (82.6%). Chronotherapy included chronoFLO (266 patients) 
(Levi et al., 1997; Giacchetti et al., 2006), chronoFL (38 patients), or irinotecan-based 
chronotherapy (56 patients) (Mormont et al., 2000, Gholam et al., 2006; Garufi et al., 2006). 
Patients received a median number of 8 courses (range, 1 to 37) of the protocol that 
immediately followed actimetry recording. Surgery for metastases resection was performed in 
22.4 % of the patients, following this new or a subsequent chemotherapy protocol. 
I<O as a Prognostic Factor for Overall Survival  
I<O ranged from 42.3% to 100%, with a median value of 97.5%. The median OS of the 
patients with I<O above the median value of 97.5% was 21.6 months [95% C.I., 17.8 to 25.5] 
as compared to 11.9 months [95% C.I., 10.4 to 13.3] in the patients with I<O equal to or less 
than 97.5% (Logrank, p < 0.001) (Figure 3A). The crude hazard ratios of I<O for overall 
survival were remarkably consistent across the nine main patient characteristics subgroups, 
including for patients with a PS of 0, 1 or 2 (Figure 4A). Results from multivariate analysis 
thus revealed that I<O was an independent prognostic factor for overall survival, along with 
performance status, number of metastatic sites, percentage of liver involvement, lung 
metastases, resection of primary tumor, and number of prior chemotherapy protocols (Table 
2). The adjusted hazard ratio corresponding to a one percent increase of I<O was 0.954 [95% 
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C.I., 0.940 to 0.968] (p<0.001).  Moreover the adjusted hazard ratios were remarkably similar 
in each of the three cohorts (Figure 4C).   
I<O as a Prognostic Factor for Progression-Free Survival 
The patients whose I<O value exceeded the median value of 97.5% had a median PFS of 9.3 
months [95% C.I., 7.6 to 11.0], as compared to 5.8 months [4.5 to 7.1] for those with a I<O 
equal to or less than 97.5%. PFS curves differed significantly between both groups (Logrank, 
p<0.001) (Figure 3B). The crude hazard ratio values were also similar in each patient 
subgroup categorized according to the 9 main patient characteristics, including PS (Figure 
4B).  The variable selection procedure retained I<O and four other prognostic factors in the 
best fitting Cox model (Table 2). The hazard ratio for I<O was highly statistically significant, 
with HR=0.970 [0.956 to 0.984], and displayed similar values in each cohort, including the 
Cohort III model with I<O, following forcing into the model to obtain parameter estimate and 
confidence interval (Figure 4D). 
 
DISCUSSION 
The rest-activity circadian rhythm was measured using the actimetry parameter I<O, which is 
the percentage of physical activity during the night that is less than the median activity during 
the day (Minors et al., 1996). This parameter was selected for this pooled analysis, since it 
displayed consistent prognostic value for survival in two previous studies, while mean activity 
and other parameters did not (Mormont et al., 2000; Innominato et al., 2009a). Here, I<O first 
proved to be a robust predictor of overall survival over the subsequent ten years, independent 
of other risk factors, in a new cohort of 142 patients with metastatic colorectal cancer. This 
finding is consistent with those obtained in two previous cohorts composed of colorectal 
cancer patients with markedly different demographic characteristics, stage of disease 
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progression, and treatment protocols (Mormont et al., 2000; Innominato et al., 2009a). The 
combined prediction among the 436 patients analyzed together reveals that the circadian rest-
activity rhythm measure robustly predicts overall survival. In particular, the patients with an 
I<O above 97.5%, indicating relatively little nighttime activity compared to median daytime 
activity, survived nearly twice as long as those with values equal to or below this value. The 
prediction was not simply an indication of circadian disruption when death was imminent, but 
rather a far longer-term indicator of outcome. A similar relation was statistically validated for 
I<O and PFS in the pooled patient population for the first time.  
Rest-activity measured with I<O is thus a sensitive measure of circadian rhythms salient to 
cancer, that integrates poor sleep at night, fatigue and physical inactivity during the day, as 
well as anorexia, and pain. This measure is in fact associated with all four variables, which are 
under circadian control (Mormont et al., 2000, Innominato et al., Innominato et al., 2009a; 
Innominato et al., 2009b). These common cancer-related problems may interact and reinforce 
one another (Spiegel, 2008). This suggests the possibility that interventions designed to 
improve sleep and diet and encourage physical activity have the potential to improve quantity 
as well as quality of life (Butler et al., 2009 ; Palesh et al., 2007 ; Spiegel, 2011). Changes in 
of I<O value primarily reflect in-bed activity, the number of minutes with activity greater than 
the daytime median. Thus, changes in daytime out-of-bed activity would modestly affect the 
out-of-bed median, unless being substantial and sustained. As a result, the dichotomy index 
I<O is in part a measure of continuity and restfulness of sleep, and its prediction of cancer 
survival integrates sleep quality into the full circadian activity rhythm. Indeed, sleep is tightly 
regulated by the circadian timing system, with established links between the circadian rhythm 
in core body temperature and sleep onset, as well as sleep quality (Borbely & Achermann, 
1992). Recent experimental data further show that increased activity during the usual activity 
span reinforces the robustness of the circadian signals arising from the pacemaker neurons in 
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the SCN (Meijer, 2011). In this context, poor I<O would indeed reflect both circadian 
disruption and poor sleep.  
It appears in particular that colorectal cancer patients with I<O score of 97.5% or less are at 
substantially higher risk for disease progression and death. However, no statistical or clinical 
threshold was identified in our study. Rather, I<O was a continuous predictor of both OS and 
PFS, that fit the definition of a biomarker: “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (Buyse et al., 2010, Wagner, 2008). 
The limitations of our study relate to the fact that the prognostic value of I<O was assessed in 
patients with metastatic colorectal cancer, at various stages of their metastatic disease, and on 
various chemotherapy protocols, though mostly including circadian-based chronotherapy. 
This study also does not rule out the hypothesis that a poor I<O could indicate a more 
aggressive type of cancer. Indeed, the patients with poorest I<O values displayed significantly 
higher levels of circulating TGFα, IL-6 or TNFα  as compared to the patients with highest 
I<O. Indeed, these cytokines can alter circadian clocks in experimental models (reviewed in 
(Levi et al., 2010). Experimental circadian disruption through suprachiasmatic nuclei ablation 
or chronic jet lag however accelerated cancer growth in tumor-bearing mice 3 (reviewed in 
(Levi et al., 2010). In the current pooled analysis, the consistent effects of I<O in each 
category of established prognostic factors and its robust and independent effect on both 
survival outcomes support that circadian disruption indeed contributes to poorer survival 
jointly with six other variables. The consistent effects of I<O on OS and PFS in each cohort, 
as well as in each category of the nine main patient characteristics, further ruled out any 
significant impact of the different chemotherapy protocols that were delivered upon the 
measured effect. Conversely, the fact that 82.6% of the patients received chronotherapy 
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prevented any reliable comparative assessment of the predictive value of I<O for 
chronotherapy versus conventional treatment delivery.  
Recent data show that chemotherapy delivery can also disrupt the rest-activity rhythm and 
result in “I<O” values equal to or below 97.5%. Interestingly, the overall survival of the 
patients with such circadian disruption was shorter than those who maintained an adequate 
rest-activity pattern while receiving chemotherapy (Innominato et al., 2012).  
The feasibility of a routine assessment of this circadian biomarker at low cost is being greatly 
enhanced through the integration of rest-activity recording within telemedicine platforms 
aiming at improving quality of life of cancer patients at home (European InCASA project 
ICT-FP7) (Levi et al., 2012). The joint detection of circadian and sleep disruption through 
rest-activity monitoring and I<O quantification provides a robust indicator of the prognosis of 
patients with metastatic colorectal cancer which is independent of the usual clinical or 
biological prognostic measures. Interventions aiming at I<O enhancement, especially when 
less than 97.5%, through concomitant increase in lively out-of-bed activity and restful in-bed 
nighttime sleep, have the potential to improve overall survival, as well as progression-free 
survival, systemic symptoms, and quality of life of patients with advanced cancer.  
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Table 1: Main characteristics of the patients in the new Cohort, as well as in updated 
Cohorts I and II, and in the Pooled population. 
Clinical and biological characteristics 
 
    
  Patient number (%)  
 Characteristic Cohort I Cohort II  Cohort III 
Pooled 
population  
Age (years), median (range) 59 (21-78) 60 (22-75) 60 (21-83) 59 (21-83) 
Sex  
Male 
Female 
115 (68.5%) 
  53 (31.5%) 
71 (56.3% ) 
55 (43.7%) 
87 (61.3%) 
55 (38.7%) 
 273 (62.6%) 
163 (37.4%) 
         
PS (WHO) †        
0 102 (60.7%) 67 (53.2%) 84 (59.6%)  253 (58.0%) 
1   52 (31.0%) 48 (38.1%) 44 (31.2%)  144 (33.0%) 
2   14 (8.3%) 11 (8.7%) 13 (9.2%)    38 (8.7 %) 
Unknown      0   0   1 (0.7%)      1 (0.2%) 
         
Primary Tumor Site        
   Colon 118 (70.2%) 95 (75.4%) 93 (65.5%)  306 (70.2%) 
   Rectum   50 (29.8%) 31 (24.6%) 49 (34.5%)  130 (29.8%) 
         
Number of Metastatic Sites †       
   None   0   1 (0.8%)   8 (5.6%)      9 (2.1%) 
   One 70 (41.7%) 56 (44.4%) 76 (53.5%)  202 (46.3%) 
   Two or more 98 (58.3%) 69 (54.8%) 58 (40.8%)  225 (51.6%) 
         
Liver metastases † 137 (81.5%) 104 (82.5%) 103 (72.5%)  344 (78.9%) 
         
Liver replacement by tumor †       
   None 31 (18.5%) 22 (17.5%) 36 (27.5%)    89 (20.4%) 
   <25% 63 (37.5%) 59 (46.8%) 46 (35.1%)  168 (38.5%) 
   >25% 74 (44.0%) 44 (34.9%) 49 (37.4%)  167 (38.3%) 
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   Unknown    0   1 (0.8%) 11 (7.7%)   12 (2.8%) 
         
Lung metastases † 71 (42.3%) 46 (36.5%) 53 (34.6%)  170 (39.0%) 
         
BMI        
   (18.5 ; 25) 88 (52.4%) 56 (44.4%) 72 (50.7%)  216 (49.5%) 
   <18.5 ; >25 77 (45.8%) 70 (55.6%) 69 (48.6%)  216 (49.5%) 
   Unknown    3 (1.8%)   0   1 (0.7%)      4 (1.0%) 
         
Median plasma concentration (range) †       
    Carcinoembryonic antigen, mg/L    44 (1-14780)  35 (0-20932) 57 (0-36845)    44 (0-36845) 
            
    CA19.9, IU/L   214 (1-78080)  82 (1-49038) 69 (1-23361)  127 (1-78080) 
Treatment History Before and After Actimetry 
 
Before actimetry     
Prior surgery for     
    Primary tumor † 160 (95.2%) 107 (94.9%) 134 (94.4%) 401 (84.9%) 
    Metastases †   53 (31.5%)     0   59 (41.5%) 112 (25.7%) 
     
Prior chemotherapy 
    Adjuvant situation 
 
  34 (20.2%) 
 
  21 (16.7%) 
 
43 (30.7%) 
 
  98 (22.5%) 
    Metastatic disease † 100 (59.5%)     4 (3.2%) 98 (69.0%) 202 (46.3%) 
      
Number of prior 
chemotherapy lines for 
metastatic disease † 
    
    None 68 (40.5%) 126 (100%) 44 (31.0%) 238 (54.6%) 
    One 56 (33.3%)     0 35 (24.6%)   91 (20.9%) 
    Two or more 44 (26.2%)     0 63 (44.4%) 107 (24.5%) 
     
Prior drugs given      
5-Fluorouracil 95 (56.5%)    0 93 (65.5%) 188 (43.1%) 
Oxaliplatin   3 (1.8%)    0 78 (55.0%)   81 (18.6%) 
Irinotecan   9 (5.4%)    0 47 (33.1%)   56 (12.8%) 
Other 24 (14.3%)    0 12 (12.7%)   36   (8.2%) 
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After actimetry     
        Surgery for metastases 53 (31.5%) 23 (18.3%) 20 (14.1%) 96 (22.4%) 
     
        Chemotherapy protocol     
ChronoFLO 137 (81.5%) 61 (48.4%) 68 (47.9%) 266 (61.0%) 
ChronoFL   31 (18.5%)   0   7 (4.9%)   38 (8.7%) 
Chrono Irinotecan ± FLO     0   0 56 (39.4%)   56 (12.8%) 
FOLFOX2     0 65 (51.6%)   6 (4.3%)   71 (16.3%) 
Other     0   0   5 (3.5%)     5 (1.1%) 
     
Chronotherapy 168 (100%) 61 (48.4%) 131 (92.3%) 360 (82.6%) 
† variables significant with p-value<0.1 in univariate Cox models for overall survival. 
Treatments after actimetry measures (baseline) were not candidate variables for the final Cox 
models. 
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Table 2: Results from Multivariate Analyses for Overall Survival and for Progression-
free survival in the Pooled Population of 436 Patients with Metastatic Colorectal Cancer 
Prognostic factor 
   Multivariate Cox Model Stratified by Cohort 
 
  HR (95 % CL) p-value 
 
Overall Survival 
 
   
 
Rest-activity rhythm (I<O)  
         
0.954 (0.940 – 0.968) <0.001 
         
Performance Status 
         1 vs 0 
 
 
1.17 
 
 
(0.92 - 1.47) 
 
<0.001 
0.19 
         2 vs 0 3.99 (2.71 – 6.00) <0.001 
    
Number of metastatic sites 
        Two  vs one 
        Three or more vs one 
 
4.49 
8.92 
 
(1.34 – 15.02) 
(2.57 – 30.94) 
<0.001 
0.015 
0.001 
    
Metastatic liver replacement   0.001 
         1-24% vs none 1.22 (0.88 – 1.68) 0.23 
         >25% vs none 1.58 (1.24 – 2.02) <0.001 
 
Lung metastases (yes vs no) 
 
0.67 (0.51 – 0.89) 0.006 
Prior chemotherapy protocols   <0.001 
        One vs none 1.68 (1.23 – 2.30) 0.001 
        Two or more vs none 2.36 (1.73 – 3.21) <0.001 
 
Primary tumor resected (yes vs no) 
 
0.52 (0.35 – 0.77) 0.001 
    
Progression-Free Survival 
 
   
 
Rest-activity rhythm (I<O)  
          
0.970 (0.956 – 0.984) <0.001 
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Performance Status 
 
         1 vs 0 
 
 
1.09 
 
 
(0.88 – 1.36) 
<0.001 
 
0.42 
         2 vs 0  
2.29 
 
(1.56 – 3.37) 
 
<0.001 
Number of metastatic sites 
 
        Two  vs one 
 
        Three or more vs one 
 
 
 
1.52 
 
1.93 
 
 
 
(0.73 – 3.17) 
 
(0.92 – 4.04) 
 
0.03 
 
 
0.27 
 
0.08 
 
Prior chemotherapy protocols   <0.001 
        One vs none 1.18 (0.89 – 1.58) 0.26 
        Two or more vs none 1.82 (1.37 – 2.42) <0.001 
Primary tumor resected (yes vs no) 0.50 (0.34 – 0.73) <0.001 
LEGEND TO FIGURES 
Figure 1: Diagram depicting the constitution of the three Cohorts and the Pooled Patient 
Population and the Studies they originate, whenever applicable. 
Figure 2: Examples of baseline rest-activity records in two patients with metastatic 
colorectal cancer. Patient #1 displayed a robust circadian rest-activity pattern, with an I<O of 
100%, while patient #2 had circadian disruption, with an I<O of 77.8%. Both patients #1 and 
#2, were 35 years old, had a WHO performance status of 0, and had received first line 
chemotherapy for liver-only metastases prior to entering the actimetry study. The survival of 
patient #1 was 37.5 months as compared to 16.6 months for patient #2.  
Figure 3: Overall survival (A) and Progression-free survival (B) curves in pooled 
population of 436 patients according to baseline rest-activity rhythm as estimated with 
I<O. I<O was determined at time “0” shown on the abscissa. Survival curves are compared 
using Logrank test. Patients are categorized according to median I<O value of 97.5% for 
visualization purposes. 
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Figure 4: Forest plots of I<O effects on overall survival and progression-free survival 
according to (A, B) main patient characteristics, and (C, D) in each cohort and in the 
pooled analysis. 
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